ADASUVE 9.1 mg INHALATION POWDER (SINGLE-DOSE)

2. What you need to know before taking ADASUVE

Do not use ADASUVE

• if you are allergic to loxapine or amoxapine;
• if you have symptoms of wheezing or shortness of breath;

• if you have lung problems such as asthma or chronic obstructive pulmonary disease (which your doctor may call "COPD").

Warnings and Precautions

Consult your doctor or nurse before starting to use ADASUVE to determine if it is suitable for you.

• ADASUVE may cause narrowing of the airways (bronchospasm) and wheezing, coughing, chest tightness, or shortness of breath. This usually occurs within 25 minutes of administration.
• Neuroleptic Malignant Syndrome (NMS) is a set of symptoms that can occur if you are taking antipsychotics, including ADASUVE. These symptoms can be high fever, muscle stiffness, irregular or rapid heartbeat. NMS can be fatal. Do not use ADASUVE again if you have had NMS.

• Antipsychotic medications like ADASUVE may cause movements that you cannot control, such as facial gestures, sticking out your tongue, hitting or biting your lips, rapid blinking, or moving your legs, arms, or fingers quickly. If this occurs, treatment with ADASUVE should be discontinued.

• ADASUVE will be used with caution in patients who are intoxicated or have delirium.

Before taking ADASUVE, inform your doctor or nurse:

• if you have or have had respiratory problems such as asthma and other chronic lung diseases, such as bronchitis or emphysema.
• if you have or have had heart problems or stroke
• if you have or have had low blood pressure or high blood pressure
• if you have or have had seizures (convulsions)
• if you have or have had glaucoma (increased eye pressure)
• if you have or have had urinary retention (incomplete emptying of the urinary bladder)
• if you have already used ADASUVE and have experienced symptoms of wheezing or shortness of breath

• if you have experienced uncontrollable muscle or eye movements, lack of coordination, constant muscle contraction, or a feeling of restlessness or if you cannot stay still

• if you are an elderly person with dementia (loss of memory and other mental abilities)

Children and Adolescents

ADASUVE is not recommended for use in children and adolescents under 18 years of age.

Using ADASUVE with Other Medications

Inform your doctor if you are taking or have recently taken or may need to take any other medication, including:

• adrenaline
• medications for treating a respiratory problem

• medications that may cause you to have seizures (e.g., clozapine, tricyclics or ISRS, tramadol, mefloquine)
• medications for treating Parkinson's disease

• lorazepam or other central-acting medications (for treating anxiety, depression, pain, or for sleeping) or other medications that cause drowsiness
• illicit drugs

• medications such as fluvoxamine, propranolol, and enoxacin, and other medications that inhibit a liver enzyme called "CYP450 1A2."

• medications for treating schizophrenia, depression, or pain, as you may be at greater risk of having seizures

The use of ADASUVE and adrenaline combined may cause low blood pressure.

Using ADASUVE with Alcohol

Since ADASUVE affects the nervous system, you should avoid consuming alcohol during treatment with ADASUVE.

Pregnancy and Breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor before using this medication. It is recommended that women do not breastfeed for 48 hours after administration of ADASUVE and discard the milk produced during this period. ADASUVE may cause the following symptoms in newborn babies of mothers who have been treated with antipsychotic medications in the last trimester of pregnancy: trembling, stiffness and/or muscle weakness, drowsiness, agitation, breathing problems, and difficulty feeding. If your baby experiences any of these symptoms, you should contact your doctor.

Driving and Using Machines

Do not drive or use tools or machines after taking ADASUVE until you know how it affects you, as the possible side effects of ADASUVE are dizziness, sedation, and drowsiness.

3. How to Use ADASUVE

Always use this medication exactly as instructed by your doctor or nurse. If you are unsure, consult your doctor or nurse again.

The recommended initial dose is 9.1 mg. After 2 hours, your doctor may prescribe a second dose after carefully considering your condition and may reduce the dose to 4.5 mg if your doctor believes this is a more suitable dose for treating your condition.

ADASUVE must be used under the supervision of a doctor or nurse.

ADASUVE is indicated for inhalation use. After the doctor or nurse has prepared ADASUVE, you will be asked to hold the device with your hand, exhale, insert the mouthpiece into your mouth, inhale the medication through the device, and hold your breath for a few seconds.

If You Take More ADASUVE Than You Should

If you think you have taken more ADASUVE than you should, inform your doctor or nurse. Patients who receive more ADASUVE than they should may experience any of the following symptoms: extreme tiredness or drowsiness, breathing problems, low blood pressure, throat irritation, or bad taste in the mouth, uncontrollable muscle or eye movements.

If you have any other questions about using this medication, ask your doctor or nurse.

4. Possible Side Effects

As with all medications, ADASUVE can cause side effects, although not everyone will experience them.

If you experience any of the following side effects, consult your doctor immediately and stop taking the medication:

• respiratory symptoms, such as wheezing, coughing, shortness of breath, or chest tightness, as this may indicate that the medication is irritating the airways (uncommon unless you have asthma or COPD);

• dizziness or fainting, as this may indicate that the medication is lowering your blood pressure (uncommon);

• worsening of agitation or confusion, especially combined with fever or muscle stiffness (rare). These can be associated with a serious condition called Neuroleptic Malignant Syndrome (NMS)

Also, consult your doctor if you experience any of the following side effects that can also occur with other forms of this medication:

Very Common(may affect more than 1 in 10 people): bad taste in the mouth or drowsiness.

Common(may affect up to 1 in 10 people): dizziness, throat irritation, dry mouth, or tiredness

Uncommon(may affect up to 1 in 100 people): uncontrollable muscle or eye movements, lack of coordination, constant muscle contraction, or a feeling of restlessness or if you cannot stay still.

Other additional effects that have been associated with long-term use of loxapine by mouth and may be relevant to ADASUVE include fainting when standing up, increased heart rate, high blood pressure, blurred vision, dry eyes, and decreased urine production.

Reporting Side Effects

If you experience any side effects, consult your doctor or nurse, even if they are side effects not listed in this package leaflet. You can also report side effects directly through the national reporting system included in Appendix V. By reporting side effects, you can help provide more information on the safety of this medication.

5. Storage of ADASUVE

Keep this medication out of sight and reach of children.

Do not use ADASUVE after the expiration date stated on the label. The expiration date is the last day of the month indicated.

Store in the original packaging until use to protect from light and moisture.

Do not use ADASUVE if the bag is open or torn or if there are signs of physical damage to the medication.

Medications should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.

6. Contents of the Pack and Further Information

The active substance is loxapine. Each single-dose inhaler contains 10 mg of loxapine and delivers 9.1 mg of loxapine.

Appearance of ADASUVE and Contents of the Pack

ADASUVE 9.1 mg powder for inhalation (single dose) consists of a white plastic, disposable, single-use inhaler containing loxapine. Each inhaler is packaged in a sealed aluminum bag. ADASUVE 9.1 mg is available in a box of 1 or 5 single-dose inhalers.

Marketing Authorization Holder

Ferrer Internacional, S.A.

Gran Vía Carlos III, 94

08028- Barcelona

Spain

Manufacturer

Ferrer Internacional, S.A.

Joan Buscalla, 1-9, 08173 Sant Cugat del Vallès

Barcelona, Spain

You can obtain more information about this medication by contacting the local representative of the marketing authorization holder:

Belgium/Belgique/BelgienLithuania

Ferrer Internacional, S.A. AOP Orphan Pharmaceuticals AG LT

Tel: +34 93 600 37 00 Tel: +370 672 12222

BulgariaLuxembourg/Luxemburg

AOP Orphan Pharmaceuticals AG BG Ferrer Internacional, S.A.

Tel: +359 2 489 9222 Tel: +34 93 600 37 00

Czech RepublicHungary

AOP Orphan Pharmaceuticals AG CZ AOP Orphan Pharmaceuticals AG HU

Tel: +420 251 512 947 Tel: +36 1 3192633

DenmarkMalta

Ferrer Internacional, S.A. Ferrer Internacional, S.A.

Tel: +34 93 600 37 00 Tel: +34 93 600 37 00

GermanyNetherlands

Ferrer Deutschland GmbH Ferrer Internacional, S.A.

Tel: +49 (0) 2407 502311 0 Tel: +34 93 600 37 00

EstoniaNorway

AOP Orphan Pharmaceuticals AG LT Ferrer Internacional, S.A.

Tel: +370 672 12222 Tel: +34 93 600 37 00

GreeceAustria

Ferrer Galenica S.A. AOP Orphan Pharmaceuticals AG

Tel: +30 210 52 81 700 Tel: +43 1 5037244-0

SpainPoland

Ferrer Farma, S.A. AOP Orphan Pharmaceuticals S.A. PL

Tel: +34 93 600 37 00 Tel: +48 22 5424068

FrancePortugal

Ferrer Internacional, S.A. Ferrer Portugal, S.A.

Tel: +34 93 600 37 00 Tel: +351 214449600

CroatiaRomania

AOP Orphan Pharmaceuticals AG Galenica S.A.

Tel: +43 1 5037244-0 Tel: +30 210 52 81 700

IrelandSlovenia

Ferrer Internacional, S.A. AOP Orphan Pharmaceuticals AG

Tel: +34 93 600 37 00 Tel: +43 1 5037244-0

IcelandSlovakia

Ferrer Internacional, S.A. AOP Orphan Pharmaceuticals AG SK

Tel: +34 93 600 37 00 Tel: +421 31 5502271

Date of Last Revision of this Package Leaflet:

Other Sources of Information

Detailed information about this medication is available on the European Medicines Agency website: http://www.ema.europa.eu.

This information is intended only for healthcare professionals:

Read all instructions before using this medication. See the SPC for more information.

Familiarize yourself with ADASUVE:The following images show the important elements of ADASUVE.

mouthpiece

indicator light

tab

• ADASUVE is packaged in a sealed bag.
• When ADASUVE is removed from the bag, the indicator light is off.
• The indicator light turns on (green) when the tab is removed. The inhaler is ready for use.

• The indicator light turns off automatically again when the medication has been inhaled. Read the following 5 steps before administering ADASUVE to a patient.

1. Open the bag

Do not open the bag until you are ready to use it.Tear the aluminum bag and remove the inhaler from its packaging.

1. Pull the tab.

Pull the plastic tab from the back of the inhaler. The green light will turn on, indicating that the inhaler is ready for use.

Use it within the first 15 minutes after removing the tab (or until the green light turns off) to avoid automatic deactivation of the inhaler.

Instruct the patient to:

1. Exhale

Hold the inhaler away from the mouth and exhale completely to empty the lungs.

1. Inhale

Inhale through the mouthpiece with a deep and continuous inspiration.

IMPORTANT: Check that the green light turns off after inhalation.

1. Hold your breath

Remove the mouthpiece from the mouth and hold your breath for a few seconds.

NOTE: If the green light remains on after the patient has inhaled, instruct the patient to repeat steps 3 to 5.